LinkedIn



Tenofovir Gel Used Before and After Sex Reduced HIV by 39 Percent

July 2010

Results of CAPRISA 004 a turning point for HIV prevention, say MTN researchers conducting VOICE

Tenofovir gel used before and after sex reduced HIV by 39 percent, raises bar for VOICE Study testing daily gel use and ARVs for preventing HIV in women

The study found tenofovir gel used in a dosing regimen timed before and after sex reduced HIV infections by 39 percent, a finding that is statistically significant and is sure to elicit excitement among the community of people engaged in HIV prevention research globally.

The study also indicated that use of the gel reduced the risk of herpes simplex virus 2 by 51 percent among women participating in the trial. an interesting observation that will be important to investigate further. The study was conducted in exemplary fashion at every step of the way. CAPRISA 004 was a double-blind, randomized controlled trial that enrolled 889 HIV-uninfected women at two sites in urban and rural.

The following materials provide further information about these exciting results:
MTN Press Release (Adobe Acrobat)
MTN Fact Sheet (Adobe Acrobat)